Cibus, Inc. entered into investment agreement with AstraZeneca PLC to subscribe for 16,000,000 ordinary shares at a price of $5 per share for gross proceeds of $80 million on November 01, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.59 USD | -.--% | +2.93% | -10.44% |
Mar. 21 | Cibus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 21 | Transcript : Cibus, Inc., Q4 2023 Earnings Call, Mar 21, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.44% | 366M | |
+7.15% | 220B | |
+6.60% | 183B | |
+9.86% | 133B | |
+24.32% | 107B | |
-0.95% | 63.05B | |
+11.04% | 51.74B | |
+4.81% | 50.47B | |
-1.43% | 40.91B | |
+24.40% | 31.91B |
- Stock Market
- Equities
- CLXT Stock
- News CALYXTPAR
- Cibus, Inc. announced that it expects to receive $80 million in funding